Shares of Veradermics, Incorporated (NYSE:MANE) climbed 17% on Monday following the release of topline findings from its Phase 2/3 clinical trial of VDPHL01, an oral extended-release minoxidil candidate for male pattern hair loss.
Study '302' enrolled 519 participants and, according to the company, met all primary and key secondary endpoints with statistical significance. The trial measured changes in non-vellus target area hair count as a primary efficacy outcome. VDPHL01 produced a mean increase of 30.3 hairs/cm2 with once-daily dosing and 37.7 hairs/cm2 with twice-daily dosing versus placebo.
Patient-reported outcomes also favored the active treatment arms. Approximately 79.3% of patients on once-daily VDPHL01 and 86.0% on twice-daily VDPHL01 reported improvement, compared with 35.6% of placebo-treated patients. When focusing on more pronounced self-assessments, 48.4% of once-daily recipients and 58.1% of twice-daily recipients reported moderate or marked improvement.
The investigational therapy demonstrated a statistically significant benefit as early as Month 2, the earliest assessment time point noted in the topline summary. Investigators judged 72.0% of once-daily patients and 81.7% of twice-daily patients to have experienced improved hair growth.
On safety, the company reported that VDPHL01 was generally well tolerated through Month 6. Overall rates of adverse events were described as similar to placebo. The study reported no treatment-related serious adverse events and no adverse events of special interest of cardiac origin. Discontinuation rates among patients receiving VDPHL01 were lower than those in the placebo arm.
If approved by regulators, VDPHL01 would represent the first FDA-approved non-hormonal oral therapy for pattern hair loss, addressing an estimated U.S. population of approximately 80 million men and women indicated in the company's summary. Veradermics also completed enrollment in a second Phase 3 male trial, Study '304', in February and said topline readout from that study is expected in the second half of 2026.
Summary
The Company reported statistically significant efficacy for VDPHL01 on multiple endpoints in a 519-patient Phase 2/3 trial, with early onset of effect at Month 2 and a tolerability profile comparable to placebo through six months.
Key Points
- Study '302' met all primary and key secondary endpoints with statistical significance in 519 participants.
- Mean increases in non-vellus target area hair count were 30.3 hairs/cm2 (once-daily) and 37.7 hairs/cm2 (twice-daily) versus placebo.
- Patient- and investigator-reported improvements were substantially higher in active arms; safety profile through Month 6 was similar to placebo.
Risks and Uncertainties
- Regulatory approval is not guaranteed; topline efficacy and tolerability in this trial do not ensure a favorable regulatory decision.
- Additional Phase 3 data from Study '304' are pending, with topline results expected in the second half of 2026, and could influence the overall efficacy and safety assessment.
- Longer-term safety beyond the six-month period reported here remains to be established.